Primary peritoneal serous carcinoma treated by cytoreductive surgery combined with hyperthermic intraperitoneal chemotherapy. A multi-institutional study of 36 patients

Eur J Surg Oncol. 2013 Jul;39(7):742-7. doi: 10.1016/j.ejso.2013.02.018. Epub 2013 Mar 16.

Abstract

Aim: Primary peritoneal serous carcinoma (PPSC) is a rare condition, histologically identical to ovarian serous carcinoma and often diagnosed at late stage. There is not any standardized treatment for PPSC. A retrospective multicentric study was performed in French speaking centers to evaluate cytoreduction surgery and Hyperthermic intraperitoneal chemotherapy (HIPEC) in the treatment of peritoneal carcinomatosis from different origins. The manuscript's aim was to study the particular population with PPSC.

Methods: Between September 1997 and July 2007, 36 patients with PPSC from 9 institutions underwent 39 procedures.

Results: Mortality and morbidity rates were 5.6% and 20.6% respectively. The overall survival at 1, 3 and 5 years are respectively 93.6, 71.5 and 57.4%. The median overall survival was not reached. By univariate analysis, the only factor that had prognostic value was PCI (p = 0.03).

Conclusions: The therapeutic approach combining cytoreductive surgery with HIPEC may achieve long-term survival in patients with PPSC.

Publication types

  • Multicenter Study

MeSH terms

  • Adult
  • Aged
  • Analysis of Variance
  • Antineoplastic Combined Chemotherapy Protocols / administration & dosage
  • Carcinoma / mortality*
  • Carcinoma / pathology
  • Carcinoma / therapy*
  • Chemotherapy, Adjuvant
  • Chemotherapy, Cancer, Regional Perfusion / methods*
  • Cohort Studies
  • Combined Modality Therapy
  • Disease-Free Survival
  • Female
  • France
  • Humans
  • Hypothermia, Induced / methods
  • Kaplan-Meier Estimate
  • Male
  • Middle Aged
  • Neoplasm Staging
  • Peritoneal Neoplasms / mortality*
  • Peritoneal Neoplasms / pathology
  • Peritoneal Neoplasms / therapy*
  • Prognosis
  • Retrospective Studies
  • Risk Assessment
  • Survival Analysis
  • Treatment Outcome